1. |
辛灵, 张虹, 张爽, 等. 多西他赛+卡铂联合曲妥珠单抗方案对早期人表皮生长因子受体2阳性乳腺癌的新辅助治疗效果. 中华外科杂志, 2021, 59(3): 222-227.
|
2. |
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol, 2021, 39(13): 1485-1505.
|
3. |
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol, 2022, 23(1): 149-160.
|
4. |
Ates O, Oksuzoglu OB, Aktas BY, et al. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data. J BUON, 2021, 26(4): 1398-1404.
|
5. |
Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol, 2021, 22(8): 1151-1161.
|
6. |
Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol, 2020, 9(3): 32-40.
|
7. |
吕民豪, 焦得闯, 吴军召, 等. 乳腺癌新辅助化疗后同侧锁骨上淋巴结病理完全缓解列线图预测模型的构建. 中华肿瘤杂志, 2022, 44(2): 160-166.
|
8. |
Hassett MJ, Li H, Burstein HJ, et al. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat, 2020, 181(1): 43-51.
|
9. |
国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2020版). 中华肿瘤杂志, 2020, 42(10): 781-797.
|
10. |
Kuerer HM, Smith BD, Krishnamurthy S, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2022, 23(12): 1517-1524.
|
11. |
Davey MG, Kerin E, O’Flaherty C, et al. Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - a retrospective cohort study. Breast, 2021, 59: 67-75.
|
12. |
Chen HL, Chen Q, Deng YC. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer. Medicine (Baltimore), 2021, 100(44): e27632. doi: 10.1097/MD.0000000000027632.
|
13. |
Katayama A, Miligy IM, Shiino S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Mod Pathol, 2021, 34(7): 1271-1281.
|
14. |
钱钧强, 张霄蓓. 乳腺癌患者细胞周期蛋白依赖性激酶5调节亚基相关蛋白2表达与新辅助化疗疗效的相关性研究. 中国全科医学, 2016, 19(35): 4346-4349.
|
15. |
Ishitobi M, Matsuda N, Tazo M, et al. Risk factors for ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieve a pathologic complete response after neoadjuvant chemotherapy. Ann Surg Oncol, 2021, 28(5): 2545-2552.
|
16. |
Abdel-Razeq H, Khalil H, Assi HI, et al. Treatment strategies for residual disease following neoadjuvant chemotherapy in patients with early-stage breast cancer. Curr Oncol, 2022, 29(8): 5810-5822.
|
17. |
Cha C, Ahn SG, Kim D, et al. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer. Int J Cancer, 2021, 149(8): 1585-1592.
|
18. |
Ma Y, Zhu M, Lv M, et al. Impact of residual disease biomarkers on the prognosis of HER2-positive breast cancer following neoadjuvant therapy. Cancer Med, 2023, 12(10): 11293-11304.
|
19. |
Hung CC, Tsai IC, Hsu CY, et al. Clinical outcomes of neoadjuvant therapy in human epidermal growth factor receptor 2 breast cancer patients: a single-center retrospective study. J Clin Med, 2022, 11(5): 1434-1441.
|
20. |
Zuo WJ, He M, Zheng H, et al. Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment. Gland Surg, 2021, 10(4): 1300-1314.
|
21. |
王伟, 张伟杰, 庄晓明, 等. 乳腺癌HER2低表达对新辅助化疗疗效影响的临床观察. 现代肿瘤医学, 2023, 31(19): 3600-3604.
|
22. |
马金平, 王海波, 张剑, 等. 雌激素受体阳性HER2阴性乳腺癌新辅助化疗反应的影响因素分析. 中国妇幼健康研究, 2023, 34(9): 68-74.
|
23. |
霍翔, 吴兵, 方德根, 等. HER2阳性乳腺癌新辅助化疗疗效的影响因素及列线图预测模型建立. 川北医学院学报, 2023, 38(1): 126-129, 136.
|
24. |
肖晶晶, 黄美玲, 延常姣, 等. Her-2阳性乳腺癌新辅助化疗联合靶向治疗获得病理完全缓解的影响因素. 实用医学杂志, 2022, 38(5): 542-546.
|
25. |
修萌, 陆瑶, 王翔, 等. 紫杉醇+卡铂密集化疗联合曲妥珠单抗新辅助治疗对比标准辅助治疗对人表皮生长因子受体2阳性且激素受体阴性乳腺癌患者生存影响的前瞻性研究. 中华肿瘤杂志, 2023, 45(8): 709-716.
|